Mechanism

Cholesterol and lipids

Connects with 53 factors and 4 health goals.

In depth

Cholesterol and lipids

⏱ 3 min read

Cholesterol is an essential molecule without which animal life would not be possible: it is part of cell membranes, it is a precursor of steroid hormones (cortisol, aldosterone, estrogens, testosterone, vitamin D), of bile acids, and of signaling molecules; the body synthesizes it endogenously in the liver in amounts far greater than those obtained from the diet and keeps its plasma levels regulated; the clinical problem is not cholesterol per se, but the imbalance among the lipoproteins that transport it, especially when there is an excess of atherogenic particles for decades.

LDL, HDL, and the oversimplification of "good and bad cholesterol"

Cholesterol travels through the blood inside lipoproteins (LDL, HDL, VLDL, chylomicrons, lipoprotein(a)) that differ in composition and metabolic behavior. The popular narrative of "good and bad cholesterol" (HDL and LDL) is pedagogically useful but highly simplified:

LDL: carries cholesterol from the liver to peripheral tissues; high levels are a robust causal factor for atherosclerosis when sustained for decades (data from Mendelian randomization, statin trials, PCSK9 inhibitor trials).
HDL: carries cholesterol from tissues to the liver for elimination; high levels are epidemiologically associated with lower cardiovascular risk, but pharmacological trials that specifically raise HDL have not shown a reduction in events, which suggests that HDL is a marker, not a causal target.
Triglycerides: high levels are associated with cardiovascular risk, especially in metabolic syndrome and diabetes; they partly reflect the presence of small, dense VLDL with an atherogenic profile.
Lipoprotein(a) or Lp(a): a hereditary cardiovascular factor relatively independent of LDL, very stable throughout life, and only modestly modifiable with interventions.

Apo B: the modern marker

The most informative marker of current atherogenic risk is apolipoprotein B (apo B), the structural protein of all potentially atherogenic lipoproteins (LDL, IDL, VLDL, Lp(a)); each atherogenic particle contains exactly one apo B, so the number directly reflects how many particles can deposit cholesterol in the arterial wall; in people with a discordant lipid profile (apparently normal LDL but many small, dense particles), apo B is more informative than LDL.

Nutritional interventions with clinical backing

Several dietary and supplement components reduce plasma LDL by documented magnitudes:

Oat beta-glucans (3-4 g/day): 5-10% LDL reduction, with a health claim approved by the FDA and EFSA.
Psyllium (10-15 g/day): 6-15% LDL reduction.
Phytosterols (2-3 g/day): 8-15% LDL reduction.
Red yeast rice (with monacolin K, a natural statin): 15-25% LDL reduction.
Aged garlic (high in S-allylcysteine): modest 5-10% reduction.
Omega-3 EPA/DHA (2-4 g/day): significant reduction in triglycerides (20-30%), modest effect on LDL.
Citrus bergamot (500-1000 mg/day): modest reduction in LDL and triglycerides.
Pharmacological niacin (1-2 g/day): potent lipid profile, but modern trials (AIM-HIGH, HPS2-THRIVE) show that added to statins it does not reduce cardiovascular events.

Synergistic dietary combination

The most effective strategy is not a single component but the dietary combination: the "portfolio diet" trial combined phytosterols + soluble fiber + soy + nuts, achieving LDL reductions of 20-30%, magnitudes comparable to low-dose statins; this approach has the added advantage of improving other cardiovascular markers (blood pressure, inflammation) and of being sustainable in the long term.

When diet is enough and when pharmacology is needed

The decision depends on individual cardiovascular risk, not just on cholesterol numbers. In people at low cardiovascular risk, dietary interventions (Mediterranean diet + specific cholesterol-lowering components) are usually sufficient. In people at high cardiovascular risk (established cardiovascular disease, diabetes, familial hypercholesterolemia, high SCORE risk), statins are the treatment of choice, with well-established data on reducing cardiovascular and all-cause mortality; nutritional interventions are complementary but not a substitute.

Saturated fat and diet: the nuanced reassessment

The classic paradigm of "reduce saturated fat to reduce cholesterol and cardiovascular events" has been nuanced: replacing saturated fat with refined carbohydrates does not reduce cardiovascular risk; replacing it with unsaturated fats (olive oil, nuts, oily fish) does; the saturated fat in whole food matrices (yogurt, cheese, dark chocolate) behaves differently metabolically from the saturated fat in processed meats or ultra-processed products.

The reasonable conclusion: prioritize a Mediterranean diet (rich in extra virgin olive oil, oily fish, nuts, legumes, vegetables, whole fruit, whole grains), moderate red meat and eliminate processed meats and ultra-processed products, maintain regular physical activity, and avoid tobacco and excess alcohol; this nutritional foundation solves the cholesterol and lipid problem in most people with moderate baseline risk.

Cholesterol and lipids

In depth